Role of Statin in Atrial Fibrillation-Related Stroke: An Angiographic Study for Collateral Flow

Background: Currently, intensive lipid lowering is recommended in patients with atherosclerotic ischemic stroke or transient ischemic attack. However, the role of statin in cardioembolic stroke is unclear. We investigated the association of statin with pretreatment collateral status in cardioembolic stroke. Methods: A collaborative study from two stroke centers in distinct geographic regions included consecutive patients with acute middle cerebral artery (MCA) infarction due to atrial fibrillation (AF) who underwent cerebral angiography. The relationship between pretreatment collateral grade and the use/dose of statin at stroke onset was assessed. The angiographic collateral grade was evaluated according to the ASITN/SIR Collateral Flow Grading System. Results: Ninety-eight patients (76 statin-naïve, 22 statin users) were included. Compared with statin-naïve patients, statin users were older and more frequently had hypertension, hyperlipidemia and coronary heart disease. Excellent collaterals (grade 3-4) were more frequently observed in statin users (11 patients, 50%) than in statin-naïve patients (21 patients, 27.6%; p = 0.049). The use of atorvastatin 10 mg equivalent or higher doses of statin was associated with excellent collaterals (p for trend = 0.025). In multiple regression analysis, prestroke statin use was independently associated with excellent collaterals (odds ratio, 7.841; 95% confidence interval, CI, 1.96-31.363; p = 0.004). Conclusions: Premorbid use of statin in AF patients is associated with excellent collateral flow. Although most statin trials excluded patients with cardioembolic stroke, our data suggests the possibility that statin may be beneficial in AF-related stroke.

[1]  V. Chair,et al.  Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. , 2014, Stroke.

[2]  H. Kamel,et al.  Statin Use During Ischemic Stroke Hospitalization Is Strongly Associated With Improved Poststroke Survival , 2012, Stroke.

[3]  E. Wijdicks,et al.  Relationship between chronic atrial fibrillation and worse outcomes in stroke patients after intravenous thrombolysis. , 2011, Archives of neurology.

[4]  D. Liebeskind,et al.  Collateral Flow Averts Hemorrhagic Transformation After Endovascular Therapy for Acute Ischemic Stroke , 2011, Stroke.

[5]  M. Zoli,et al.  The Atorvastatin During Ischemic Stroke Study: A Pilot Randomized Controlled Trial , 2011, Clinical neuropharmacology.

[6]  A. RossNaylor.  Letter by Naylor Regarding Article, “Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association” , 2011 .

[7]  K. Furie,et al.  Statin Treatment and Functional Outcome After Ischemic Stroke: Case–Control and Meta-Analysis , 2011, Stroke.

[8]  H. An,et al.  Preexisting Statin Use Is Associated With Greater Reperfusion in Hyperacute Ischemic Stroke , 2011, Stroke.

[9]  L. Daly,et al.  Association Between Acute Statin Therapy, Survival, and Improved Functional Outcome After Ischemic Stroke: The North Dublin Population Stroke Study , 2011, Stroke.

[10]  D. Liebeskind,et al.  Collateral Flow Predicts Response to Endovascular Therapy for Acute Ischemic Stroke , 2011, Stroke.

[11]  J. Koyama,et al.  Early intervention with rosuvastatin decreases the lipid components of the plaque in acute coronary syndrome: analysis using integrated backscatter IVUS (ELAN study). , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[12]  K. Rayner,et al.  Pre-Procedural Atorvastatin Mobilizes Endothelial Progenitor Cells: Clues to the Salutary Effects of Statins on Healing of Stented Human Arteries , 2011, PloS one.

[13]  Irene Katzan,et al.  Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. , 2011, Stroke.

[14]  P. Barber,et al.  Pathophysiological Determinants of Worse Stroke Outcome in Atrial Fibrillation , 2010, Cerebrovascular Diseases.

[15]  P. Kelly,et al.  Stroke Subtype Classification to Mechanism-Specific and Undetermined Categories by TOAST, A-S-C-O, and Causative Classification System: Direct Comparison in the North Dublin Population Stroke Study , 2010, Stroke.

[16]  J. V. van Engelshoven,et al.  Symptomatic Patients With Mild and Moderate Carotid Stenosis: Plaque Features at MRI and Association With Cardiovascular Risk Factors and Statin Use , 2010, Stroke.

[17]  Douglas Losordo,et al.  Role of endothelial progenitor cells during ischemia-induced vasculogenesis and collateral formation. , 2010, Microvascular research.

[18]  A. Blann,et al.  Effects of atorvastatin on circulating CD34+/CD133+/ CD45− progenitor cells and indices of angiogenesis (vascular endothelial growth factor and the angiopoietins 1 and 2) in atherosclerotic vascular disease and diabetes mellitus , 2010, Journal of internal medicine.

[19]  K. Furie,et al.  Collateral Vessels on CT Angiography Predict Outcome in Acute Ischemic Stroke , 2009, Stroke.

[20]  David S. Liebeskind,et al.  Clinical determinants of infarct pattern subtypes in large vessel atherosclerotic stroke , 2009, Journal of Neurology.

[21]  Max Wintermark,et al.  MR and CT Monitoring of Recanalization, Reperfusion, and Penumbra Salvage: Everything That Recanalizes Does Not Necessarily Reperfuse! , 2009, Stroke.

[22]  M. Chopp,et al.  Simvastatin Increases Notch Signaling Activity and Promotes Arteriogenesis After Stroke , 2009, Stroke.

[23]  K. Kimura,et al.  Atrial fibrillation as an independent predictor for no early recanalization after IV-t-PA in acute ischemic stroke , 2008, Journal of the Neurological Sciences.

[24]  C. Molina,et al.  Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial , 2007, European journal of neurology.

[25]  F. Sellke,et al.  Atorvastatin impairs the myocardial angiogenic response to chronic ischemia in normocholesterolemic swine. , 2008, The Journal of thoracic and cardiovascular surgery.

[26]  F Viñuela,et al.  Impact of collateral flow on tissue fate in acute ischaemic stroke , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[27]  S. Grundmann,et al.  Arteriogenesis: basic mechanisms and therapeutic stimulation , 2007, European journal of clinical investigation.

[28]  G. Duckwiler,et al.  Statin enhancement of collateralization in acute stroke , 2007, Neurology.

[29]  J. Farmer.  High-dose atorvastatin after stroke or transient ischemic attack. , 2007, Current atherosclerosis reports.

[30]  M. Hennerici,et al.  High-dose atorvastatin after stroke or transient ischemic attack. , 2006, The New England journal of medicine.

[31]  K. Furie,et al.  An evidence‐based causative classification system for acute ischemic stroke , 2005, Annals of neurology.

[32]  B. Meier,et al.  Effect of statin treatment on coronary collateral flow in patients with coronary artery disease , 2004, Heart.

[33]  W. Rand,et al.  Statin use is associated with enhanced collateralization of severely diseased coronary arteries. , 2003, American heart journal.

[34]  R. Higashida,et al.  Trial Design and Reporting Standards for Intra-Arterial Cerebral Thrombolysis for Acute Ischemic Stroke , 2003, Stroke.

[35]  Yi Li,et al.  Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke , 2003, Annals of neurology.

[36]  C. Heeschen,et al.  Statins Have Biphasic Effects on Angiogenesis , 2002, Circulation.

[37]  M. Voskuil,et al.  Stimulation of arteriogenesis; a new concept for the treatment of arterial occlusive disease. , 2001, Cardiovascular research.

[38]  I. Shiojima,et al.  The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. , 2000, Nature Medicine.

[39]  D. Hunninghake,et al.  Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) , 1998, The American journal of cardiology.

[40]  A. U. Rickel,et al.  Guidelines for Prevention, I , 1998 .

[41]  E. Almeida,et al.  RAPID REVERSAL OF ENDOTHELIAL DYSFUNCTION IN HYPERCHOLESTEROLAEMIC RABBITS TREATED WITH SIMVASTATIN AND PRAVASTATIN , 1997, Clinical and experimental pharmacology & physiology.